Bayer launches Betaferon in China

28-Sep-2010 - China

Bayer Schering Pharma announced the upcoming launch in China of Betaferon® (interferon beta-1b) for the treatment of relapsing-remitting forms of multiple sclerosis (MS). Betaferon is already approved in over 100 countries worldwide. With Betaferon and Gadovist®1.0, which was also recently launched in China, Bayer HealthCare China aims to provide Chinese multiple sclerosis patients with a comprehensive range of services from diagnosis to therapy. Gadovist 1.0, a contrast agent for use in magnetic resonance imaging (MRI), has been approved in China for the diagnosis of diseases affecting the central nervous system, including MS, and for blood-vessel imaging.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances